Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03029988 · ClinicalTrials.gov registry record · Phase 1
An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.
A Phase 1 study, sponsored by Navidea Biopharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03029988 is a Phase 1 study that was terminated before completion, run by Navidea Biopharmaceuticals. The registered enrollment target is 3 participants.
The verdict
NCT03029988, a Phase 1 study, was terminated before completion, sponsored by Navidea Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
Interventions
- DRUG Tilmanocept (Technetium Tc 99m tilmanocept Injection)
- PROCEDURE SPECT/CT Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-07-26 |
| Est. Completion | 2018-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03029988
The ClinicalTrials.gov registry entry for NCT03029988 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navidea Biopharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tilmanocept (Technetium Tc 99m tilmanocept Injection) is the first listed.
NCT03029988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03029988 about?
NCT03029988 is a clinical study titled "An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.". Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
What is the current status of trial NCT03029988?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-07-26. Estimated completion is 2018-09-24.
What interventions are being tested in trial NCT03029988?
The interventions under investigation include: Tilmanocept (Technetium Tc 99m tilmanocept Injection) (DRUG), SPECT/CT Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT03029988?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.